Abstract
The new therapy for the patient (pt) with drug-resistant mCRPC (dr-mCRPC) is a definite unmet medical need. The ORR of dr-mCRPC pts were only 7% to 17% in second to fourth line settings. Other studies reported that AKT inhibitor plus anti-androgen is a potential treatment for dr-mCRPC. This study assessed the safety and efficacy of combination therapy of afuresertib (a AKT inhibitor) and LAE001 (a dual inhibitor of CYP17A1 (testosterone synthesis) and CYP11B2 (aldosterone synthase) in dr-mCRPC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
